Literature DB >> 22672482

ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.

G Bettoni1, R Palla, C Valsecchi, D Consonni, L A Lotta, S M Trisolini, I Mancini, K M Musallam, F R Rosendaal, F Peyvandi.   

Abstract

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening disease. Of surviving patients, 45% develops an exacerbation or a late recurrence. Severe ADAMTS-13 deficiency, both during the acute episode and remission, is a well-established predictor of recurrence. The predictive value of anti-ADAMTS-13 antibodies, their inhibitory activity and Ig class subtype for disease recurrence is still to be established.
OBJECTIVES: To analyze ADAMTS-13-related biomarkers (ADAMTS-13 and anti-ADAMTS-13 immunoglobulins, classes and subclasses) and their potential relationship with prognosis. PATIENTS/
METHODS: In 115 patients with TTP, we assessed the association between levels of these biomarkers and the severity of acute episodes; we analysed also the hazard ratio (HR) and 95% confidence interval (CI) of recurrence in association with biomarkers levels retrieved at the previous acute episode or during remission, using Cox regression models.
RESULTS: During the acute phase, higher IgA, IgG1 and IgG3 titers showed the strongest association with acute episode severity. In the survival analyzes, the only biomarker significantly associated with a high hazard of recurrence after an acute episode was the presence of IgG. Conversly, low ADAMTS-13 activity or antigen levels (<10%), the presence of ADAMTS-13 inhibitor or IgG during remission were all significantly associated with a higher hazard of recurrence.
CONCLUSIONS: Both the Ig class and subclass are of predictive value for acute episode severity in patients with TTP. Although markers that could predict the risk of recurrence in the acute phase are limited, a thorough assessment of ADAMTS-13-related parameters during remission is warranted.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672482     DOI: 10.1111/j.1538-7836.2012.04808.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  18 in total

1.  Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Silvia Ferrari; Kristina Palavra; Bernadette Gruber; Johanna A Kremer Hovinga; Paul Knöbl; Claudine Caron; Caroline Cromwell; Louis Aledort; Barbara Plaimauer; Peter L Turecek; Hanspeter Rottensteiner; Friedrich Scheiflinger
Journal:  Haematologica       Date:  2013-11-15       Impact factor: 9.941

Review 2.  A new biological marker candidate in female reproductive system diseases: Matrix metalloproteinase with thrombospondin motifs (ADAMTS).

Authors:  Kadir Demircan; İsmail Cömertoğlu; Sümeyya Akyol; Beyza Nur Yiğitoğlu; Esma Sarıkaya
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-12-01

3.  Purtscher retinopathies: are we aiming at the wrong target?

Authors:  I H Yusuf; S-L Watson
Journal:  Eye (Lond)       Date:  2013-04-05       Impact factor: 3.775

Review 4.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

5.  Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection.

Authors:  Filipa Caeiro Alves; Rute Aguiar; Pedro Pessegueiro; Carlos Pires
Journal:  BMJ Case Rep       Date:  2018-03-17

6.  Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.

Authors:  Jingrui Sui; Wenjing Cao; Konstantine Halkidis; Mohammad S Abdelgawwad; Nicole K Kocher; Bryan Guillory; Lance A Williams; Radhika Gangaraju; Marisa B Marques; X Long Zheng
Journal:  Blood Adv       Date:  2019-12-23

7.  The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

Authors:  Martin Bommer; Manuela Wölfle-Guter; Stephan Bohl; Florian Kuchenbauer
Journal:  Dtsch Arztebl Int       Date:  2018-05-11       Impact factor: 5.594

8.  Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases.

Authors:  Yanxia Bi; Jian Su; Shengru Zhou; Yingjie Zhao; Yan Zhang; Huihui Zhang; Mingdong Liu; Aiwu Zhou; Jianrong Xu; Meng Pan; Yiming Zhao; Fubin Li
Journal:  Elife       Date:  2022-08-03       Impact factor: 8.713

9.  An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.

Authors:  J Muia; W Gao; S L Haberichter; L Dolatshahi; J Zhu; L A Westfield; S C Covill; K D Friedman; J E Sadler
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

Review 10.  The potential roles of Von Willebrand factor and neutrophil extracellular traps in the natural history of hypertrophic and hypertensive cardiomyopathy.

Authors:  Richard C Becker; A Phillip Owens; Sakthivel Sadayappan
Journal:  Thromb Res       Date:  2020-05-07       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.